• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    US Pharmaceutical Contract Development Manufacturing Organization Market

    ID: MRFR/Pharma/20199-HCR
    128 Pages
    Rahul Gotadki
    September 2025

    United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Report Information By Service (Pharmaceutical Manufacturing Services, Drug Development Services and Biologics Manufacturing Services), By End User (Small & Mid-Size Pharma, Generic Pharmaceutical Companies, Big Pharma and Other End Users) – United States Market Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Report -Forecast till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    US Pharmaceutical Contract Development Manufacturing Organization Market Summary

    The Global United States Pharmaceutical Contract Development and Manufacturing Organization market is projected to grow significantly from 235.94 USD Billion in 2024 to 541.32 USD Billion by 2035.

    Key Market Trends & Highlights

    United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate of 7.84 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 541.32 USD Billion, indicating robust growth opportunities.
    • In 2024, the market is valued at 235.94 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of advanced manufacturing technologies due to increasing demand for customized pharmaceuticals is a major market driver.

    Market Size & Forecast

    2024 Market Size 235.94 (USD Billion)
    2035 Market Size 541.32 (USD Billion)
    CAGR (2025 - 2035) 7.84%

    Major Players

    Apple Inc (US), Microsoft Corp (US), Amazon.com Inc (US), Alphabet Inc (US), Berkshire Hathaway Inc (US), Tesla Inc (US), Meta Platforms Inc (US), Johnson & Johnson (US), Visa Inc (US), Procter & Gamble Co (US)

    US Pharmaceutical Contract Development Manufacturing Organization Market Trends

    Rising launch of efficient pharmaceutical solutions is driving the market growth

    Pharmaceutical businesses are being encouraged to launch efficient pharmaceutical solutions to speed up the treatment process for the rising incidence of chronic diseases and the aging population in the US. The World Health Organization (WHO) predicts that by 2020, non-communicable diseases (NCDs) will account for 57% of the burden of disease. 

    Additionally, the ability of CDMOs to streamline the pharmaceutical supply chain and the implementation of the one-stop-shop concept to introduce efficient drug goods into the market is anticipated to fuel the expansion of the CDMO market in the United States over the projected period. In the upcoming years, it is expected that the CDMO market CAGR will grow more rapidly in the United States due to the expanding therapeutic applications of biologics and the growing share of pipeline compounds.

    In addition, the growth of the contract development and manufacturing organizations sector is anticipated to be fueled by rising infrastructure expenditures and the ability of United States CDMOs to offer completely integrated services through cutting-edge technologies. Due to the availability of cutting-edge R&D & production platforms and trained workers, the outsourcing of manufacturing processes to CDMOs has also resulted in rapid regulatory clearances in the United States. 

    A lot of CDMOs are putting a lot of effort into capital investments in order to diversify geographically and create new compounds. October 2017 saw the announcement by CordenPharma International of a strategic €3.7 million investment in their Swiss small molecule API production facility. Additionally, one of the main factors expected to drive the expansion of the CDMO market throughout the projected period is the augmentation of the number of new entrants via partnerships.

    The United States Pharmaceutical Contract Development and Manufacturing Organization market appears to be evolving rapidly, driven by increasing demand for outsourcing and a growing emphasis on innovation in drug development.

    U.S. Food and Drug Administration (FDA)

    US Pharmaceutical Contract Development Manufacturing Organization Market Drivers

    Focus on Cost Efficiency

    Cost efficiency remains a pivotal driver in the Global United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Industry. Pharmaceutical companies increasingly seek to outsource manufacturing processes to CDMOs to reduce operational costs and enhance productivity. By leveraging the expertise and infrastructure of CDMOs, companies can avoid the substantial capital investment required for in-house production. This trend is likely to continue, as the market is projected to grow at a CAGR of 7.84% from 2025 to 2035, reaching 541.32 USD Billion by 2035. Consequently, the emphasis on cost-effective solutions is reshaping the dynamics of pharmaceutical manufacturing.

    Market Growth Projections

    The Global United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Industry is poised for remarkable growth, with projections indicating a market size of 235.94 USD Billion in 2024 and an anticipated increase to 541.32 USD Billion by 2035. This growth trajectory, characterized by a CAGR of 7.84% from 2025 to 2035, underscores the expanding role of CDMOs in the pharmaceutical landscape. As companies increasingly outsource their manufacturing needs, CDMOs are likely to play a crucial role in facilitating the development and distribution of new therapies. This upward trend reflects the ongoing evolution of the pharmaceutical industry and the strategic importance of CDMOs in meeting future healthcare demands.

    Increasing Demand for Biologics

    The Global United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Industry is witnessing a surge in demand for biologics, driven by advancements in biotechnology and an increasing prevalence of chronic diseases. Biologics, which include monoclonal antibodies and vaccines, require specialized manufacturing processes that CDMOs are well-equipped to handle. As the market for biologics expands, projected to reach 235.94 USD Billion in 2024, CDMOs are positioned to capitalize on this growth by offering tailored solutions that meet regulatory standards and ensure product efficacy. This trend indicates a robust future for CDMOs as they adapt to the evolving landscape of biologic manufacturing.

    Growing Demand for Personalized Medicine

    The growing demand for personalized medicine is a transformative driver in the Global United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Industry. As healthcare shifts towards tailored therapies that cater to individual patient needs, CDMOs are increasingly required to provide flexible manufacturing solutions that accommodate small batch sizes and diverse formulations. This trend is indicative of a broader movement towards precision medicine, which is gaining traction among pharmaceutical companies. The ability of CDMOs to adapt to these requirements positions them favorably in a market projected to experience substantial growth, further emphasizing their role in the development of innovative therapeutic solutions.

    Regulatory Compliance and Quality Assurance

    Regulatory compliance and quality assurance are critical factors influencing the Global United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Industry. As regulatory bodies impose stringent guidelines to ensure drug safety and efficacy, CDMOs play a vital role in helping pharmaceutical companies navigate these complexities. By adhering to Good Manufacturing Practices (GMP) and maintaining high-quality standards, CDMOs enhance the credibility of their clients' products. This focus on compliance not only mitigates risks associated with regulatory penalties but also fosters trust among consumers and healthcare providers. As a result, the demand for CDMOs with robust quality assurance processes is expected to rise.

    Technological Advancements in Manufacturing

    Technological advancements are significantly shaping the Global United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Industry. Innovations such as automation, artificial intelligence, and advanced analytics are streamlining manufacturing processes, enhancing efficiency, and reducing time-to-market for new drugs. CDMOs that adopt these technologies can offer more agile and responsive services, catering to the fast-paced demands of the pharmaceutical sector. As the industry evolves, the integration of cutting-edge technologies is likely to become a competitive differentiator for CDMOs, enabling them to meet the increasing expectations of pharmaceutical companies for faster and more reliable production capabilities.

    Market Segment Insights

    United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Service Insights

    The United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market segmentation, based on Service, includes Pharmaceutical Manufacturing Services, Drug Development Services, and Biologics Manufacturing Services. The pharmaceutical manufacturing services segment held a substantial stake, which may be attributable to factors including the growing demand for biologics and biosimilars in the region, as well as the expanding pharmaceutical and biopharmaceutical industries worldwide. Additionally, major industry participants are spending money on drug development and discovery, which is expected to fuel the segment's expansion.

    Figure 1: United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, by Service, 2022 & 2032 (USD Billion)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review        

    United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) End User Insights

    The United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market segmentation, based on End User, includes Small & Mid-Size Pharma, Generic Pharmaceutical Companies, Big Pharma, and Other End Users. Throughout the projection period, the big pharma category is anticipated to have the highest CAGR. Some of the key factors expected to propel the market's growth are increased investment in the big pharma firms of gene and cell therapies, a rise in the number of biologics undergoing pipeline investigations, and the growing demand for targeted medication therapy.

    United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Country Insights

    For small and mid-sized pharmaceutical companies, the process of finding and developing new drugs is extremely costly and time-consuming. Nonetheless, drug development activities are outsourced to contract development and research groups by pharmaceutical companies, who choose this more cost-effective and efficient approach in the US. Serious repercussions are incurred by the company, and the brand name when guidelines and regulations are not followed by the appropriate authorities and defective pharmaceuticals are produced. 

    As a result, in the pharmaceutical sector, following regulatory requirements is crucial. Major pharmaceutical corporations in the United States are also restocking the market with increased investments in this area. In order to satisfy market and outsourcing demand, the United States contract manufacturing organizations, or CMOs, have expanded from their original provision of basic manufacturing services to a broad package of services.

    Get more detailed insights about United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Research Report -Forecast till 2032

    Regional Insights

    Key Players and Competitive Insights

    Leading market players are putting more on R&D to increase the range of products they offer, which will support the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market's expansion. In addition, market players are engaging in a range of calculated initiatives to increase their presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) industry must provide reasonably priced goods.

    Major players in the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market are engaging in research and development activities in an effort to boost market demand includes Thermo Fisher Scientific Inc. (US), Catalent (US), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany).

    Key Companies in the US Pharmaceutical Contract Development Manufacturing Organization Market market include

    Industry Developments

    February 2022: Recipharm AB (Sweden) purchased Arranta Bio (U.S.) in order to expand its service offerings and establish a solid foothold in the U.S. by providing scientifically distinct contract research and manufacturing services for ATMPs.

    February 2021: Charles River Laboratories International, Inc. (United States) paid $875 million to Cognate BioServices, Inc. (United States) to expand their capabilities in cell and gene therapy CDMOs.

    February 2020: MaSTherCell Global Inc. (Belgium) was purchased by Catalent Inc. (U.S.) for $315 million with the intention of utilizing MaSTherCell's distinctive portfolio of technologies, capabilities, and associated analytical services to lead the field with its cell & genetic therapy platforms.

    Future Outlook

    US Pharmaceutical Contract Development Manufacturing Organization Market Future Outlook

    The United States Pharmaceutical CDMO Market is projected to grow at a 7.84% CAGR from 2024 to 2035, driven by increasing outsourcing, technological advancements, and demand for personalized medicine.

    New opportunities lie in:

    • Invest in advanced manufacturing technologies to enhance production efficiency and reduce costs.
    • Expand service offerings in biologics and gene therapies to capture emerging market segments.
    • Develop strategic partnerships with biotech firms to foster innovation and accelerate product development.

    By 2035, the market is expected to be robust, reflecting substantial growth and innovation.

    Market Segmentation

    United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Service Outlook

    • Pharmaceutical Manufacturing Services
    • Drug Development Services
    • Biologics Manufacturing Services

    United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) End User Outlook

    • Small & Mid-Size Pharma
    • Generic Pharmaceutical Companies
    • Big Pharma
    • Other End Users

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 USD 46.27Billion
    Market Size 2024 USD 50.34Billion
    Market Size 2032 USD 97.07 Billion
    Compound Annual Growth Rate (CAGR) 6.86% (2023-2032)
    Base Year 2022
    Market Forecast Period 2023-2032
    Historical Data 2018-2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product, Distribution Channel, and Region
    Countries Covered United States
    Key Companies Profiled Thermo Fisher Scientific Inc. (US), Catalent (US), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Evonik Industries AG (Germany)
    Key Market Opportunities ·         High expense of developing drugs in-house is probably going to fuel market expansion. ·         Rising demand for pharmaceutical products will fuel growth.
    Key Market Dynamics ·         Increase in strategic alliances and investments to support CDMOs, or contract development and manufacturing organizations ·         Growing biologics therapeutic applications and a larger proportion of pipeline compounds are expected to fuel the CDMO sector's growth in the upcoming years.

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the size of the United States market for Contract Development and Manufacturing Organizations (CDOs)?

    In 2022, the pharmaceutical contract development and manufacturing organization (CDMMO) market in the United States was estimated to be worth USD 46.27 billion.

    What is the United States pharmaceutical CDMO (contract development and manufacturing organization) market growth rate?

    From 2023 to 2032, the market is expected to expand at a compound annual growth rate (CAGR) of 6.86%.

    Who are the major companies in the United States market for Contract Development and Manufacturing Organizations (CDOs)?

    AbbVie (US), Aenova Group (Germany), Consort Medical (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), Evonik Industries AG (Germany), Lonza Group (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), and Thermo Fisher Scientific Inc. (US) are the major players in the market.

    In the United States pharmaceutical Contract Development and Manufacturing Organization (CDMMO) market, which service was the leader?

    In 2022, the market was dominated by the Pharmaceutical Manufacturing Services segment.

    In the United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market, which End User held the biggest market share?

    The market share that the Big Pharma category held was the highest.

    1. EXECUTIVE SUMMARY
    2. MARKET INTRODUCTION
      1. Definition
      2. Scope of the Study
    3. Research Objective
      1. Assumptions
        1. Limitations
    4. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
    5. Secondary Research
      1. Primary Research
        1. Primary
    6. Interviews and Information Gathering Process
      1. Breakdown of Primary
    7. Respondents
      1. Forecasting Model
      2. Market Size
    8. Estimation
      1. Bottom-Up Approach
        1. Top-Down
    9. Approach
      1. Data Triangulation
      2. Validation
    10. MARKET DYNAMICS
      1. Overview
      2. Drivers
    11. Restraints
      1. Opportunities
    12. MARKET FACTOR ANALYSIS
    13. Value Chain Analysis
      1. Porter’s Five Forces Analysis
    14. Bargaining Power of Suppliers
      1. Bargaining Power of Buyers
    15. Threat of New Entrants
      1. Threat of Substitutes
    16. Intensity of Rivalry
      1. COVID-19 Impact Analysis 
    17. Market Impact Analysis
      1. Regional Impact
    18. Opportunity and Threat Analysis
    19. UNITED STATES PHARMACEUTICAL CONTRACT
    20. DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET, BY SERVICE
    21. Overview
      1. Pharmaceutical Manufacturing Services
    22. Drug Development Services 
      1. Biologics Manufacturing Services
    23. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION
    24. (CDMO) MARKET, BY END USER
      1. Overview
      2. Small
    25. & Mid-Size Pharma
      1. Generic Pharmaceutical Companies
    26. Big Pharma 
      1. Other End Users
    27. COMPETITIVE LANDSCAPE
      1. Overview
      2. Competitive Analysis
    28. Market Share Analysis
      1. Major Growth Strategy in the United States
    29. Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market, 
    30. Competitive Benchmarking
      1. Leading Players in Terms of Number of
    31. Developments in the United States Pharmaceutical Contract Development and Manufacturing
    32. Organization (CDMO) Market, 
      1. Key Developments and Growth
    33. Strategies
      1. New Product Launch/Service Deployment
    34. Merger &Acquisitions
      1. Joint Ventures
    35. Major Players Financial Matrix 
      1. Sales & Operating
    36. Income, 2022
      1. Major Players R&D Expenditure.2022
    37. COMPANY PROFILES
      1. Thermo Fisher Scientific Inc. (US)
    38. Company Overview
      1. Financial Overview
        1. Products
    39. Offered
      1. Key Developments
        1. SWOT Analysis
    40. Key Strategies
      1. Catalent (US)
        1. Company Overview
    41. Financial Overview
      1. Products Offered
        1. Key
    42. Developments
      1. SWOT Analysis
        1. Key Strategies
    43. Lonza Group (Switzerland)
      1. Company Overview
    44. Financial Overview
      1. Products Offered
        1. Key
    45. Developments
      1. SWOT Analysis
        1. Key Strategies
    46. Recipharm AB (Sweden)
      1. Company Overview
    47. Financial Overview
      1. Products Offered
        1. Key
    48. Developments
      1. SWOT Analysis
        1. Key Strategies
    49. Vetter Pharma International GMBH (Germany)
      1. Company Overview
    50. Financial Overview
      1. Products Offered
        1. Key
    51. Developments
      1. SWOT Analysis
        1. Key Strategies
    52. FAMAR Health Care Services (Greece)
      1. Company Overview
    53. Financial Overview
      1. Products Offered
        1. Key
    54. Developments
      1. SWOT Analysis
        1. Key Strategies
    55. AbbVie (US)
      1. Company Overview
        1. Financial
    56. Overview
      1. Products Offered
        1. Key Developments
    57. SWOT Analysis
      1. Key Strategies
      2. Aenova Group
    58. (Germany)
      1. Company Overview
        1. Financial Overview
    59. Products Offered
      1. Key Developments
        1. SWOT
    60. Analysis
      1. Key Strategies
      2. Consort Medical
    61. (UK))
      1. Company Overview
        1. Financial Overview
    62. Products Offered
      1. Key Developments
        1. SWOT
    63. Analysis
      1. Key Strategies
      2. Almac Group (UK)
    64. Company Overview
      1. Financial Overview
    65. Products Offered
      1. Key Developments
        1. SWOT
    66. Analysis
      1. Key Strategies
      2. Siegfried Holding
    67. AG (Switzerland)
      1. Company Overview
        1. Financial
    68. Overview
      1. Products Offered
        1. Key Developments
    69. SWOT Analysis
      1. Key Strategies
      2. Boehringer
    70. Ingelheim International GmbH (Germany)
      1. Company Overview
    71. Financial Overview
      1. Products Offered
    72. Key Developments
      1. SWOT Analysis
        1. Key Strategies
    73. Evonik Industries AG (Germany)
      1. Company Overview
    74. Financial Overview
      1. Products Offered
    75. Key Developments
      1. SWOT Analysis
        1. Key Strategies
      2. References
      3. Related Reports
    76. LIST
    77. OF TABLES
    78. AND MANUFACTURING ORGANIZATION (CDMO) MARKET, SYNOPSIS, 2018-2032
    79. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION
    80. (CDMO) MARKET, ESTIMATES & FORECAST, 2018-2032(USD BILLION)
    81. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION
    82. (CDMO) MARKET, BY SERVICE, 2018-2032 (USD BILLION)
    83. STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO)
    84. MARKET, BY END USER, 2018-2032 (USD BILLION)
    85. LIST
    86. OF FIGURES
    87. STRUCTURE FOR THE UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING
    88. ORGANIZATION (CDMO) MARKET
    89. STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO)
    90. MARKET
    91. AND MANUFACTURING ORGANIZATION (CDMO) MARKET, SHARE (%), BY SERVICE, 2022
    92. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION
    93. (CDMO) MARKET, SHARE (%), BY END USER, 2022
    94. PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) MARKET:
    95. COMPANY SHARE ANALYSIS, 2022 (%)
    96. INC. (US): FINANCIAL OVERVIEW SNAPSHOT
    97. INC. (US): SWOT ANALYSIS
    98. SNAPSHOT
    99. LONZA GROUP (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
    100. LONZA GROUP (SWITZERLAND): SWOT ANALYSIS
    101. FINANCIAL OVERVIEW SNAPSHOT
    102. ANALYSIS
    103. OVERVIEW SNAPSHOT
    104. SWOT ANALYSIS
    105. OVERVIEW SNAPSHOT
    106. ANALYSIS
    107. ABBVIE (US): SWOT ANALYSIS
    108. OVERVIEW SNAPSHOT
    109. CONSORT MEDICAL (UK): FINANCIAL OVERVIEW SNAPSHOT
    110. MEDICAL (UK): SWOT ANALYSIS
    111. OVERVIEW SNAPSHOT
    112. SIEGFRIED HOLDING AG (SWITZERLAND): FINANCIAL OVERVIEW SNAPSHOT
    113. SIEGFRIED HOLDING AG (SWITZERLAND): SWOT ANALYSIS
    114. INGELHEIM INTERNATIONAL GMBH (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
    115. BOEHRINGER INGELHEIM INTERNATIONAL GMBH (GERMANY): SWOT ANALYSIS
    116. EVONIK INDUSTRIES AG (GERMANY): FINANCIAL OVERVIEW SNAPSHOT
    117. EVONIK INDUSTRIES AG (GERMANY): SWOT ANALYSIS 

    United States Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials